These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10370667)

  • 1. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
    Yao GB; Ji YY; Xu DZ; Gao J; Wu XH; Zhang QB; Hu DC
    Hepatogastroenterology; 1999; 46(26):1059-64. PubMed ID: 10370667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
    Yao G; Ji Y; Yang M; Xu D; Gao J; Wu X; Zhang Q; Hu D
    Chin Med J (Engl); 1998 Oct; 111(10):922-6. PubMed ID: 11189241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.
    Kullavanuaya P; Treeprasertsuk S; Thong-Ngam D; Chaermthai K; Gonlachanvit S; Suwanagool P
    J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S462-8. PubMed ID: 11529376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained remission and viraemia in chronic hepatitis C treated with recombinant alpha-interferon (rIFN-alpha).
    Bresci G; Gambardella L; Parisi G; Banti S; Scatena F; Bertoni M; Capria A
    Int J Clin Pharmacol Res; 1995; 15(5-6):175-9. PubMed ID: 8835615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a.
    Tabaru A; Narita R; Hiura M; Abe S; Otsuki M
    Am J Gastroenterol; 2005 Apr; 100(4):862-7. PubMed ID: 15784033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C.
    Sarin SK; Goyal A; Kumar S; Guptan RC; Hashmi AZ; Sakhuja P; Malhotra V
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):42-8. PubMed ID: 14969836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon.
    Oliveri F; Santantonio T; Bellati G; Colombatto P; Mels GC; Carriero L; Dastoli G; Pastore G; Ideo G; Bonino F; Brunetto MR
    Am J Gastroenterol; 1999 May; 94(5):1366-72. PubMed ID: 10235220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
    Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial].
    Rolachon A; Kézachian G; Causse X; Baud M; Leroy V; Maynard-Muet M; Pasquier D; Zarski JP
    Gastroenterol Clin Biol; 1997; 21(12):924-8. PubMed ID: 9587555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group.
    Chemello L; Bonetti P; Cavalletto L; Talato F; Donadon V; Casarin P; Belussi F; Frezza M; Noventa F; Pontisso P
    Hepatology; 1995 Sep; 22(3):700-6. PubMed ID: 7657272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study.
    Ascione A; De Luca M; Canestrini C; Di Costanzo GG; Raimondo G; Longo G; Manns MP; Tillmann HL; Forte GB; Rocco P; Biceglia O; Faleo D; Vinelli F; Cela EM; Amitrano L; Addario L; Gigliotti T
    Ital J Gastroenterol Hepatol; 1998 Oct; 30(5):517-23. PubMed ID: 9836109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.